Invesco Ltd. Has $309.48 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Invesco Ltd. raised its holdings in Edwards Lifesciences Co. (NYSE:EW) by 30.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,180,471 shares of the medical research company’s stock after buying an additional 982,170 shares during the quarter. Invesco Ltd. owned 0.71% of Edwards Lifesciences worth $309,480,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in shares of Edwards Lifesciences by 10.4% during the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock valued at $5,117,845,000 after acquiring an additional 6,537,494 shares during the last quarter. Wellington Management Group LLP lifted its position in Edwards Lifesciences by 5.3% in the 4th quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company’s stock worth $2,458,601,000 after buying an additional 1,678,154 shares during the last quarter. Geode Capital Management LLC lifted its position in Edwards Lifesciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company’s stock worth $1,007,520,000 after buying an additional 126,194 shares during the last quarter. Fisher Asset Management LLC lifted its position in Edwards Lifesciences by 7.7% in the 4th quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock worth $723,664,000 after buying an additional 696,965 shares during the last quarter. Finally, Norges Bank bought a new stake in Edwards Lifesciences in the 4th quarter worth approximately $610,895,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of recent research reports. Morgan Stanley boosted their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 12th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $82.00 to $90.00 in a research report on Monday, December 16th. Citigroup boosted their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Finally, Canaccord Genuity Group boosted their target price on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research note on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $79.95.

Insider Buying and Selling

In other news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the sale, the chief financial officer now directly owns 30,561 shares in the company, valued at approximately $2,315,301.36. This trade represents a 26.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bernard J. Zovighian sold 6,164 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the transaction, the chief executive officer now directly owns 59,083 shares in the company, valued at $4,106,859.33. This trade represents a 9.45 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 62,853 shares of company stock worth $4,534,247. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $69.86 on Thursday. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $95.25. The stock has a 50-day moving average of $71.43 and a 200 day moving average of $70.66. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $41.07 billion, a price-to-earnings ratio of 10.02, a PEG ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.